Conference Call with Divi's Laboratories Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Conference Call with Divi's Laboratories Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Divi's Laboratories announced Q3FY25 results Consolidated total income Rs 2,401 crore for Q3FY25 as against a consolidated total income of Rs 1,950 crore for Q3FY24. Profit before tax (PBT) for Q3FY25 amounted to Rs 726 crore as against a PBT of Rs 489 crore for Q3FY24. Profit after tax (PAT) for Q3FY25 amounted to Rs 589 crore as against a PAT of Rs 358 crore for Q3FY24. For the Q3FY25, we have forex gain of Rs 10 crore as against a gain of Rs 18 crore during Q3FY24. Result PDF